USANA Health Sciences, Inc.(USNA)Earnings, Financials & Key RatiosUSANA Health Sciences, Inc. (USNA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company holds $162.8 million in cash, the volatility in net income and the recent net loss of $6.5 million in 2025Q3 suggest that fundamental performance remains too fragile for a high-conviction position.
USANA Health Sciences, Inc. (USNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
USANA Health Sciences, Inc. (USNA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.61vs $0.44+38.6% | $250Mvs $241M+3.7% |
| Q1 2026 | Feb 17, 2026 | $0.60vs $0.41+46.3% | $226Mvs $226M+0.1% |
| Q4 2025 | Oct 21, 2025 | $0.15vs $0.25-160.0% | $214Mvs $220M-2.8% |
| Q3 2025 | Jul 22, 2025 | $0.74vs $0.54+37.0% | $236Mvs $226M+4.4% |
Recent stock market news and headlines for USANA Health Sciences, Inc. (USNA)
SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- As World Cup soccer players push through pressure, fatigue, setbacks and global expectations, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE: USNA), says their pursuit of victory carries a lesson that reaches far beyond the field. It comes down to one of the 12 principles from his book, All the Right Reasons: The Piano Principle.
PAGS, USNA, GM, NEXA and AVT stand out after passing low price-to-book value screens, highlighting five stocks that merit a closer look in July.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Nexa Resources, Avnet, StoneCo and USANA Health stand out as lower oil prices ease inflation worries and boost the case for value stocks.
USANA Health Sciences is undergoing restructuring, causing temporary margin pressure but positioning for significant future profit expansion. Rise Wellness posted 740% revenue growth, but gross margin fell to 7.1% due to promotional discounts; margin recovery is expected as restocking begins at regular prices. Hiya's revenue dropped 13.3% amid higher CAC from Meta algorithm changes; in-house manufacturing should drive cost savings in H2.
Key metrics vs top competitors for USANA Health Sciences, Inc. (USNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.38 | $413.2M | 38.59 | 8.28% | 1.16% | 1.84% | — | |
| $5.17 | $251.01M | 1.63 | -14.26% | 3.78% | 6.84% | — | |
| $21.75 | $382.47M | 20.52 | 5.67% | 4.06% | 12.08% | — | |
| $1.82 | $20.31M | -23.73 | -7.42% | -3.03% | -4.88% | — | |
| $13.14 | $1.36B | 5.97 | 0.89% | 4.67% | — | — | |
| $1.18 | $110.17M | -9.08 | 4.13% | -6.21% | -79.7% | — |
USANA Health Sciences, Inc. (USNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
USANA Health Sciences, Inc. (USNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 20, 2026·SEC
May 5, 2026·SEC
Feb 18, 2026·SEC
Get notified when USNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
USANA Health Sciences, Inc. (USNA) stock FAQ — growth, dividends, profitability & financials explained
USANA Health Sciences, Inc. (USNA) reported $925.9M in revenue for fiscal year 2025. This represents a 1533% increase from $56.7M in 1996.
USANA Health Sciences, Inc. (USNA) grew revenue by 8.3% over the past year. This is steady growth.
Yes, USANA Health Sciences, Inc. (USNA) is profitable, generating $8.9M in net income for fiscal year 2025 (1.2% net margin).
USANA Health Sciences, Inc. (USNA) has a return on equity (ROE) of 1.8%. This is below average, suggesting room for improvement.
USANA Health Sciences, Inc. (USNA) generated $3.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
